Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir

Mustafa Ascha; Mona Ascha; N N Zein; N Alkhouri; B Eghtesad; K Abu-Elmagd; T Diago; I A Hanouneh

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir

Int J Organ Transplant Med. 2015;6(2):86-90.

Authors

Mustafa Ascha¹, Mona Ascha¹, N N Zein¹, N Alkhouri¹, B Eghtesad², K Abu-Elmagd², T Diago², I A Hanouneh¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.
² Department of General Surgery, Transplant Center, Cleveland Clinic, Cleveland, Ohio, United States.

PMID: 26082832
PMCID: PMC4464282

Abstract

Hepatitis C virus (HCV) infection remains a leading indication for orthotopic liver transplantation (OLT) worldwide. Recurrence of HCV following OLT is universal. There is scarcity of data on the post-OLT treatment of HCV genotype-4-the predominant genotype in North Africa and the Middle East. Herein, we present three patients who have experienced HCV genotype-4 recurrence post-OLT. All three patients were interferon-naive and were treated with simeprivir (SIM) and sofosbuvir (SOF) combination therapy for 12-24 weeks. The data from this case series show that SIM+SOF are well-tolerated and effective for achieving viral clearance in HCV genotype-4 post-OLT patients. Given the limited nature of a case series, further research must be pursued regarding post-OLT HCV genotype-4 responses to direct-acting anti-viral therapy.

Keywords: Genotype; Hepacivirus; Interferon; Liver transplantation.

Publication types

Case Reports